0001209191-18-039187.txt : 20180622
0001209191-18-039187.hdr.sgml : 20180622
20180622161724
ACCESSION NUMBER: 0001209191-18-039187
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180620
FILED AS OF DATE: 20180622
DATE AS OF CHANGE: 20180622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwieterman William D
CENTRAL INDEX KEY: 0001403961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21990
FILM NUMBER: 18914723
MAIL ADDRESS:
STREET 1: C/O OXIGENE, INC., 230 THIRD AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0000908259
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 133679168
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-635-7000
MAIL ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: OXIGENE INC
DATE OF NAME CHANGE: 19930628
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-20
0
0000908259
MATEON THERAPEUTICS INC
MATN
0001403961
Schwieterman William D
C/O MATEON THERAPEUTICS, INC.
701 GATEWAY BLVD., SUITE 210
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Employee Stock Option (Right to Buy)
0.22
2018-06-20
4
A
0
500000
0.00
A
2028-06-20
Common Stock
500000
500000
D
Employee Stock Option (Right to Buy)
0.22
2018-06-20
4
A
0
500000
0.00
A
2028-06-20
Common Stock
500000
500000
D
Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as President and Chief Executive Officer.
The Options will vest in twelve equal monthly installments beginning one month after the date of grant.
Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as President and Chief Executive Officer.
/s/ Megan N. Gates, attorney-in-fact
2018-06-22